Stockscreener 앱 받기
231.20
3.54%
7.91
시간 외 거래:
233.56
2.36
+1.02%
전일 마감가:
$223.29
열려 있는:
$223.49
하루 거래량:
812.46K
Relative Volume:
1.30
시가총액:
$15.16B
수익:
$1.01B
순이익/손실:
$581.90M
주가수익비율:
26.06
EPS:
8.8733
순현금흐름:
$50.57M
1주 성능:
+8.43%
1개월 성능:
-3.87%
6개월 성능:
+9.00%
1년 성능:
+30.10%
1일 변동 폭
$222.70
$234.59
1주일 범위
$208.00
$234.59
52주 변동 폭
$160.86
$250.74
Ascendis Pharma A S Stock (ASND) Company Profile
Compare ASND vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ASND
Ascendis Pharma A S
|
231.20 | 14.64B | 1.01B | 581.90M | 50.57M | 8.8733 |
VRTX
Vertex Pharmaceuticals Inc
|
453.17 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
614.73 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
878.49 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
281.90 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
156.58 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
Ascendis Pharma A S Stock (ASND) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-03-16 | 재개 | Jefferies | Buy |
| 2026-01-28 | 개시 | Barclays | Overweight |
| 2025-11-18 | 개시 | Wolfe Research | Peer Perform |
| 2025-10-17 | 개시 | Raymond James | Strong Buy |
| 2025-07-03 | 재개 | Morgan Stanley | Overweight |
| 2025-05-05 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2025-04-16 | 개시 | RBC Capital Mkts | Outperform |
| 2025-01-07 | 개시 | UBS | Buy |
| 2024-09-05 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2024-06-25 | 업그레이드 | TD Cowen | Hold → Buy |
| 2024-05-31 | 개시 | Stifel | Buy |
| 2023-12-20 | 개시 | Jefferies | Buy |
| 2023-06-14 | 재개 | Credit Suisse | Neutral |
| 2023-04-05 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2023-04-04 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2023-04-03 | 다운그레이드 | Credit Suisse | Outperform → Neutral |
| 2022-10-20 | 개시 | Goldman | Buy |
| 2022-08-30 | 재개 | Berenberg | Buy |
| 2022-03-28 | 재개 | Wedbush | Outperform |
| 2022-03-15 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2022-03-01 | 개시 | Citigroup | Buy |
| 2022-02-14 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2022-01-06 | 개시 | Cowen | Market Perform |
| 2021-12-08 | 개시 | Wells Fargo | Overweight |
| 2021-10-20 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2021-03-30 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2021-03-11 | 재개 | Stifel | Buy |
| 2020-12-17 | 개시 | Berenberg | Buy |
| 2020-09-14 | 재개 | JP Morgan | Overweight |
| 2020-03-20 | 개시 | Oppenheimer | Outperform |
| 2019-10-11 | 개시 | Morgan Stanley | Overweight |
| 2019-03-25 | 개시 | Evercore ISI | Outperform |
| 2019-01-24 | 개시 | Cantor Fitzgerald | Overweight |
| 2019-01-24 | 업그레이드 | Leerink Partners | Mkt Perform → Outperform |
| 2018-06-26 | 개시 | Stifel | Buy |
| 2018-04-02 | 재확인 | Leerink Partners | Mkt Perform |
| 2017-05-11 | 개시 | JP Morgan | Overweight |
| 2017-03-09 | 다운그레이드 | Leerink Partners | Outperform → Mkt Perform |
| 2017-02-09 | 개시 | Credit Suisse | Outperform |
| 2016-09-26 | 개시 | Wedbush | Outperform |
모두보기
Ascendis Pharma A S 주식(ASND)의 최신 뉴스
Oppenheimer reiterates Ascendis Pharma stock rating on drug data - Investing.com
Oppenheimer reiterates Ascendis Pharma stock rating on drug data By Investing.com - Investing.com Canada
Ascendis Pharma Posts Strong 3.5-Year Phase 3 Data for TransCon PTH in Hypoparathyroidism - TipRanks
Long-term TransCon PTH data from Ascendis Pharma (ASND) show sustained benefits - Stock Titan
Ascendis Pharma A/S (ASND) Presents at Endocrine Society's Annual Meeting (ENDO 2026)Slideshow - Seeking Alpha
Ascendis Pharma completes Phase 3 PaTHway Trial - TipRanks
symbol__ Stock Quote Price and Forecast - CNN
(ASND) Risk Channels and Responsive Allocation - Stock Traders Daily
Ascendis Pharma Reports Sustained Efficacy and Safety of TransCon PTH in Phase 3 PaTHway Trial for Hypoparathyroidism After Three and a Half Years - Quiver Quantitative
Hormone shot helps hypoparathyroidism patients cut daily calcium and vitamin D - Stock Titan
Ascendis Pharma's TransCon PTH shows 5-year success in hypoparathyroidism treatment, boosting stock. - Pluang
Why Is Ascendis Pharma Stock Gaining Friday? - Benzinga
Ascendis boasts of long-term Yorvipath data for hypoparathyroidism - MSN
Ascendis Pharma Reports Five-Year TransCon PTH Data Showing Sustained Benefits in Hypoparathyroidism - TipRanks
Five-year TransCon PTH trial results reported by Ascendis Pharma (ASND) - Stock Titan
Ascendis reports 5-year data for hypoparathyroidism drug - Investing.com UK
Ascendis reports 5-year data for hypoparathyroidism drug By Investing.com - Investing.com Australia
Ascendis Pharma Says TransCon PTH Shows Sustained Efficacy at 5 Years - Moomoo
5-year trial: drug frees most hypoparathyroidism patients from supplements - Stock Titan
5-Year Phase 2 Data Show TransCon® PTH Replicated Systemic - GlobeNewswire
Ascendis Pharma Named Among Top Profitable Growth Stocks: Market Recognition BuildsMid-Term Outlook - newsline.com
Ascendis Pharma grants 27,030 employee warrants at $213.23 per share By Investing.com - Investing.com South Africa
Ascendis Pharma Grants New Employee Warrants as Part of Updated Equity Incentive Plan - TipRanks
Ascendis Pharma grants 27,030 employee warrants at $213.23 per share - Investing.com
[6-K] Ascendis Pharma A/S Current Report (Foreign Issuer) | ASND SEC FilingForm 6-K - Stock Titan
Ascendis Pharma (ASND):10 Most Profitable Growth Stocks to Buy - Yahoo Finance
Oppenheimer reiterates Ascendis Pharma stock rating amid ITC case By Investing.com - Investing.com Australia
Oppenheimer reiterates Ascendis Pharma stock rating amid ITC case - Investing.com
10 Most Profitable Growth Stocks to Buy - Insider Monkey
Ascendis Pharma A/S to Present Latest Data on Endocrinology Rare Disease Programs at ENDO 2026 - Quiver Quantitative
Ascendis to Showcase Advances in Treatment of Rare Endocrine Diseases at ENDO 2026 - GlobeNewswire Inc.
Assessing Ascendis Pharma (NasdaqGS:ASND) Valuation After Recent Share Price Weakness - simplywall.st
Assessing Ascendis Pharma (ASND) Valuation After Recent Share Price Weakness - Yahoo Finance
Why Ascendis Pharma Stock Is Sinking Today - TipRanks
Ascendis Pharma A/S (ASND) Stock Analysis: Unlocking a 40% Upside Potential with Strong Buy Ratings - DirectorsTalk Interviews
Capital International Ltd. CA Sells 4,811 Shares of Ascendis Pharma A/S $ASND - MarketBeat
ASND Technical Analysis | Trend, Signals & Chart Patterns - ChartMill
Ascendis Pharma A/S Stock 12‑Month Price Target Raised to $295.6, Implies 40% Upside - TradingView
TD Asset Management Inc Has $49.90 Million Position in Ascendis Pharma A/S $ASND - MarketBeat
The Option Play Of The Week (NASDAQ:ASND) - Seeking Alpha
Westfield Capital Management Co. LP Cuts Stake in Ascendis Pharma A/S $ASND - MarketBeat
Ascendis Pharma reports trial data on achondroplasia treatment - Investing.com
Ascendis Pharma’s YUVIWEL gains orphan drug exclusivity in U.S. - Investing.com
ASND Q1 2026 Earnings: EPS Misses Estimates by Wide Margin; Stock Falls 1%Estimate Dispersion - newsline.com
Insider Buying: Scott Smith Acquires Additional Shares of Ascend - GuruFocus
Ascendis Pharma A/S - MLQ.ai
Insider Buying: Scott Smith Acquires Additional Shares of Ascendis Pharma AS (ASND) - GuruFocus
Ascendis Pharma (ASND) CFO acquires 100 Ordinary Shares in open-market buy - Stock Titan
AlphaCentric Life Sciences and Healthcare Fund's Ascendis Pharma AS(ASND) Holding History - GuruFocus
(ASND) Movement as an Input in Quant Signal Sets - Stock Traders Daily
Insider Buying: Jean Bienaime Acquires Additional Shares of Asce - GuruFocus
Ascendis Pharma A S (ASND) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Ascendis Pharma A S 주식 (ASND) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| BIENAIME JEAN JACQUES | Director |
May 29 '26 |
Buy |
223.12 |
500 |
111,562 |
900 |
| SMITH SCOTT THOMAS | EVP & Chief Financial Officer |
May 29 '26 |
Buy |
223.32 |
250 |
55,830 |
4,267 |
| BIENAIME JEAN JACQUES | Director |
May 26 '26 |
Buy |
237.80 |
400 |
95,120 |
400 |
| JENSEN FLEMMING STEEN | See Remarks |
May 11 '26 |
Sale |
238.49 |
19,460 |
4,641,021 |
0 |
1.27%
1.43%
자본화:
|
볼륨(24시간):